pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

30,043 catalysts · 10,512 approval · 5,000 device 510k · 4,728 grant · 3,012 8k filing · 2,000 device pma · 2,000 device recall

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-10: 42 catalysts2026-08-11: 16 catalysts2026-08-12: 19 catalysts2026-08-13: 19 catalysts2026-08-14: 4 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 1 catalyst2026-08-18: 2 catalysts2026-08-19: 2 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 1 catalyst2026-08-27: 1 catalyst2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 1 catalyst2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 12 catalysts2026-10-29: 20 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts2026-11-02: 8 catalysts2026-11-03: 16 catalysts2026-11-04: 22 catalysts2026-11-05: 36 catalysts2026-11-06: 2 catalysts2026-11-07: 0 catalysts2026-11-08: 0 catalysts
view
agendamonth
sort
soonestlatesttypesponsoralpha
from 2016-07-27×clear all
type
  • approval10,512
  • device 510k5,000
  • grant4,728
  • 8k filing3,012
  • device pma2,000
  • device recall2,000
  • recall1,126
  • device adverse event1,000
  • earnings577
  • phase 2 completion172
  • therapy area
    • Oncology148
    • Infectious Disease46
    • Cardiology37
    • Immunology35
    • Dermatology31
    • Pulmonology22
    • Women's Health19
    • Ophthalmology16
    • Pain15

    Week of Jul 25, 2016

    8
    ›Jul 27, 2016approval3667d agoADLYXIN (LIXISENATIDE) — FDA approvalADLYXIN

    Sponsor: SANOFI-AVENTIS US. Form: SOLUTION. Route: SUBCUTANEOUS

    full page →ADLYXIN →fda approvals ↗
    ›Jul 27, 2016approval3667d agoPRIMAQUINE (PRIMAQUINE PHOSPHATE) — FDA approvalprimaquine phosphate

    Sponsor: SANOFI AVENTIS US. Form: TABLET. Route: ORAL

    full page →primaquine phosphate →fda approvals ↗
    ›Jul 27, 2016approval3667d agoTRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN (ACETAMINOPHEN) — FDA approvalAmneal Pharmaceuticals, Inc.

    Sponsor: AMNEAL PHARMS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Jul 27, 2016approval3667d agoTRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN (ACETAMINOPHEN) — FDA approvalAmneal Pharmaceuticals, Inc.

    Sponsor: AMNEAL PHARMS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Jul 28, 2016approval3666d agoALEVE (NAPROXEN SODIUM) — FDA approvalNAPROXEN SODIUM

    Sponsor: BAYER. Form: TABLET. Route: ORAL

    full page →NAPROXEN SODIUM →fda approvals ↗
    ›Jul 28, 2016approval3666d agoCAPRELSA (VANDETANIB) — FDA approvalvandetanib

    Sponsor: GENZYME CORP. Form: TABLET. Route: ORAL

    full page →vandetanib →fda approvals ↗
    ›Jul 28, 2016approval3666d agoALLOPURINOL — FDA approvalMylan Pharmaceuticals Inc

    Sponsor: REGCON HOLDINGS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Jul 29, 2016approval3665d agoDUREZOL (DIFLUPREDNATE) — FDA approvalDIFLUPREDNATE

    Sponsor: SANDOZ. Form: EMULSION. Route: OPHTHALMIC

    full page →DIFLUPREDNATE →fda approvals ↗

    Week of Aug 1, 2016

    14
    ›Aug 1, 2016approval3662d agoLEVETIRACETAM — FDA approvalAprecia Pharmaceuticals LLC

    Sponsor: CHARTWELL MOLECULAR. Form: SOLUTION. Route: ORAL

    full page →fda approvals ↗
    ›Aug 1, 2016approval

    Week of Aug 8, 2016

    7
    ›Aug 9, 2016approval3654d agoSUSTOL (GRANISETRON) — FDA approvalgranisetron ER

    Sponsor: HERON THERAPS INC. Form: INJECTABLE. Route: SUBCUTANEOUS

    full page →granisetron ER →fda approvals ↗
    ›Aug 9, 2016approval

    Week of Aug 15, 2016

    6
    ›Aug 17, 2016approval3646d agoXARELTO (RIVAROXABAN) — FDA approvalJanssen Therapeutics

    Sponsor: JANSSEN PHARMS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Aug 17, 2016approval

    Week of Aug 22, 2016

    8
    ›Aug 22, 2016approval3641d agoFENTANYL-75 (FENTANYL) — FDA approvalDifGen Pharmaceuticals LLC

    Sponsor: DIFGEN PHARMS. Form: FILM, EXTENDED RELEASE. Route: TRANSDERMAL

    full page →fda approvals ↗
    ›Aug 25, 2016approval

    Week of Aug 29, 2016

    7
    ›Aug 30, 2016approval3633d agoKESIMPTA (OFATUMUMAB) — FDA approvalKESIMPTA

    Sponsor: NOVARTIS. Form: SOLUTION. Route: SUBCUTANEOUS

    full page →KESIMPTA →fda approvals ↗
    ›Aug 30, 2016approval
    ← prev
    page 1 of 601
    next →
    3662d ago
    LEVETIRACETAM — FDA approvalAprecia Pharmaceuticals LLC

    Sponsor: CHARTWELL MOLECULAR. Form: SOLUTION. Route: ORAL

    full page →fda approvals ↗
    ›Aug 1, 2016approval3662d agoPEPCID AC (FAMOTIDINE) — FDA approvalKenvue Inc.

    Sponsor: KENVUE BRANDS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Aug 2, 2016approval3661d agoCLEOCIN HYDROCHLORIDE (CLINDAMYCIN HYDROCHLORIDE) — FDA approvalclindamycin hydrochloride

    Sponsor: PFIZER. Form: CAPSULE. Route: ORAL

    full page →clindamycin hydrochloride →fda approvals ↗
    ›Aug 2, 2016approval3661d agoFLONASE SENSIMIST ALLERGY RELIEF (FLUTICASONE FUROATE) — FDA approvalGlaxoSmithKline LLC

    Sponsor: HALEON US HOLDINGS. Form: SPRAY, METERED. Route: NASAL

    full page →fda approvals ↗
    ›Aug 4, 2016approval3659d agoDEPO-SUBQ PROVERA 104 (MEDROXYPROGESTERONE ACETATE) — FDA approvalmedroxyprogesterone acetate

    Sponsor: PFIZER. Form: INJECTABLE. Route: SUBCUTANEOUS

    full page →medroxyprogesterone acetate →fda approvals ↗
    ›Aug 5, 2016approval3658d agoKEYTRUDA (PEMBROLIZUMAB) — FDA approvalpembrolizumab

    Sponsor: MERCK SHARP DOHME. Form: SOLUTION. Route: INTRAVENOUS

    full page →pembrolizumab →fda approvals ↗
    ›Aug 5, 2016approval3658d agoCLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER (CLINDAMYCIN PHOSPHATE) — FDA approvalCLEOCIN

    Sponsor: PFIZER. Form: INJECTABLE. Route: INJECTION

    full page →CLEOCIN →fda approvals ↗
    ›Aug 5, 2016approval3658d agoCLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER (CLINDAMYCIN PHOSPHATE) — FDA approvalCLEOCIN

    Sponsor: PFIZER. Form: INJECTABLE. Route: INJECTION

    full page →CLEOCIN →fda approvals ↗
    ›Aug 5, 2016approval3658d agoCLEOCIN PHOSPHATE (CLINDAMYCIN PHOSPHATE) — FDA approvalCLEOCIN

    Sponsor: PFIZER. Form: INJECTABLE. Route: INJECTION

    full page →CLEOCIN →fda approvals ↗
    ›Aug 5, 2016approval3658d agoCLEOCIN PHOSPHATE (CLINDAMYCIN PHOSPHATE) — FDA approvalCLEOCIN

    Sponsor: PFIZER. Form: INJECTABLE. Route: INJECTION

    full page →CLEOCIN →fda approvals ↗
    ›Aug 5, 2016approval3658d agoORKAMBI (IVACAFTOR) — FDA approval(ivacaftor + lumacaftor)

    Sponsor: VERTEX PHARMS INC. Form: TABLET. Route: ORAL

    full page →(ivacaftor + lumacaftor) →fda approvals ↗
    ›Aug 5, 2016approval3658d agoBUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE (BUPRENORPHINE HYDROCHLORIDE) — FDA approvalIGC Pharma, Inc.

    Sponsor: SUN PHARM. Form: TABLET. Route: SUBLINGUAL

    full page →fda approvals ↗
    ›Aug 5, 2016approval3658d agoMIFEPREX (MIFEPRISTONE) — FDA approvalCORCEPT THERAPEUTICS INC

    Sponsor: DANCO LABS LLC. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    3654d ago
    IRBESARTAN — FDA approvalIRBESARTAN

    Sponsor: MACLEODS PHARMS LTD. Form: TABLET. Route: ORAL

    full page →IRBESARTAN →fda approvals ↗
    ›Aug 9, 2016approval3654d agoIRBESARTAN — FDA approvalIRBESARTAN

    Sponsor: AUROBINDO PHARMA LTD. Form: TABLET. Route: ORAL

    full page →IRBESARTAN →fda approvals ↗
    ›Aug 9, 2016approval3654d agoIRBESARTAN — FDA approvalIRBESARTAN

    Sponsor: HETERO LABS LTD V. Form: TABLET. Route: ORAL

    full page →IRBESARTAN →fda approvals ↗
    ›Aug 9, 2016approval3654d agoIRBESARTAN — FDA approvalIRBESARTAN

    Sponsor: HETERO LABS LTD V. Form: TABLET. Route: ORAL

    full page →IRBESARTAN →fda approvals ↗
    ›Aug 9, 2016approval3654d agoHEPARIN SODIUM — FDA approvalHEPARIN SODIUM

    Sponsor: PFIZER. Form: INJECTABLE. Route: INJECTION

    full page →HEPARIN SODIUM →fda approvals ↗
    ›Aug 14, 2016approval3649d agoLITHIUM CARBONATE — FDA approvalCamber Pharmaceuticals Inc

    Sponsor: PHARMOBEDIENT. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    3646d ago
    BUPROPION HYDROCHLORIDE — FDA approvalSciegen Pharmaceuticals Inc

    Sponsor: SCIEGEN PHARMS. Form: TABLET, EXTENDED RELEASE. Route: ORAL

    full page →fda approvals ↗
    ›Aug 18, 2016approval3645d agoTROKENDI XR (TOPIRAMATE) — FDA approvalSUPERNUS PHARMACEUTICALS, INC.

    Sponsor: SUPERNUS PHARMS. Form: CAPSULE, EXTENDED RELEASE. Route: ORAL

    full page →fda approvals ↗
    ›Aug 18, 2016approval3645d agoABILIFY MAINTENA KIT (ARIPIPRAZOLE) — FDA approvalaripiprazole LA

    Sponsor: OTSUKA PHARM CO LTD. Form: FOR SUSPENSION, EXTENDED RELEASE. Route: INTRAMUSCULAR

    full page →aripiprazole LA →fda approvals ↗
    ›Aug 19, 2016approval3644d agoBUPROPION HYDROCHLORIDE — FDA approvalBUPROPION HYDROCHLORIDE

    Sponsor: HERITAGE PHARMA. Form: TABLET. Route: ORAL

    full page →BUPROPION HYDROCHLORIDE →fda approvals ↗
    ›Aug 19, 2016approval3644d agoDAYTRANA (METHYLPHENIDATE) — FDA approvalNoven Pharmaceuticals Inc

    Sponsor: NOVEN PHARMS INC. Form: FILM, EXTENDED RELEASE. Route: TRANSDERMAL

    full page →fda approvals ↗
    3638d ago
    XARELTO (RIVAROXABAN) — FDA approvalJanssen Therapeutics

    Sponsor: JANSSEN PHARMS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Aug 25, 2016approval3638d agoXARELTO (RIVAROXABAN) — FDA approvalJanssen Therapeutics

    Sponsor: JANSSEN PHARMS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Aug 25, 2016approval3638d agoGLEEVEC (IMATINIB MESYLATE) — FDA approvalImatinib Mesylate Shilpa

    Sponsor: NOVARTIS. Form: TABLET. Route: ORAL

    full page →Imatinib Mesylate Shilpa →fda approvals ↗
    ›Aug 25, 2016approval3638d agoGLEEVEC (IMATINIB MESYLATE) — FDA approvalImatinib Mesylate Shilpa

    Sponsor: NOVARTIS. Form: TABLET. Route: ORAL

    full page →Imatinib Mesylate Shilpa →fda approvals ↗
    ›Aug 26, 2016approval3637d agoCARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER (NICARDIPINE HYDROCHLORIDE) — FDA approvalAmneal Pharmaceuticals, Inc.

    Sponsor: CHIESI. Form: INJECTABLE. Route: INTRAVENOUS

    full page →fda approvals ↗
    ›Aug 26, 2016approval3637d agoSTIVARGA (REGORAFENIB) — FDA approvalBayer AG

    Sponsor: BAYER HLTHCARE. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Aug 26, 2016approval3637d agoVISINE (NAPHAZOLINE HYDROCHLORIDE) — FDA approval

    Sponsor: KENVUE BRANDS. Form: SOLUTION/DROPS. Route: OPHTHALMIC

    full page →fda approvals ↗
    3633d ago
    WELLBUTRIN XL (BUPROPION HYDROCHLORIDE) — FDA approvalIpca Pharmaceuticals Inc

    Sponsor: BAUSCH. Form: TABLET, EXTENDED RELEASE. Route: ORAL

    full page →fda approvals ↗
    ›Aug 30, 2016approval3633d agoFORFIVO XL (BUPROPION HYDROCHLORIDE) — FDA approvalTWi Pharmaceuticals Inc

    Sponsor: TWI PHARMS. Form: TABLET, EXTENDED RELEASE. Route: ORAL

    full page →fda approvals ↗
    ›Aug 30, 2016approval3633d agoAPLENZIN (BUPROPION HYDROBROMIDE) — FDA approvalBausch Health US LLC

    Sponsor: BAUSCH. Form: TABLET, EXTENDED RELEASE. Route: ORAL

    full page →fda approvals ↗
    ›Aug 30, 2016approval3633d agoBLINCYTO (BLINATUMOMAB) — FDA approvalblinatumomab

    Sponsor: AMGEN. Form: INJECTABLE. Route: INJECTION

    full page →blinatumomab →fda approvals ↗
    ›Aug 30, 2016approval3633d agoBLINCYTO (BLINATUMOMAB) — FDA approvalblinatumomab

    Sponsor: AMGEN. Form: INJECTABLE. Route: INJECTION

    full page →blinatumomab →fda approvals ↗
    ›Aug 31, 2016approval3632d agoLINZESS (LINACLOTIDE) — FDA approvallinaclotide

    Sponsor: ABBVIE. Form: CAPSULE. Route: ORAL

    full page →linaclotide →fda approvals ↗
    $HRTX0.5114+3.06%
    $NVS156.33+1.37%
    $AMRX18.14+0.39%
    $AMRX18.14+0.39%
    $KVUE19.05-0.94%
    $PFE26.76+2.14%
    $PFE26.76+2.14%
    $PFE26.76+2.14%
    $PFE26.76+2.14%
    $PFE26.76+2.14%
    $PFE26.76+2.14%
    $PFE26.76+2.14%
    $VERX11.94+3.20%
    $IGC0.2670+0.41%
    $CORT113.90+2.83%
    $SUPN46.87-1.62%
    $NVS156.33+1.37%
    $AMRX18.14+0.39%
    $NVS156.33+1.37%
    $AMGN410.94+1.51%
    $AMGN410.94+1.51%
    $ABBV246.04+0.89%